Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

French pharma major Sanofi (Euronext: SAN) has shared new progress from its mid- to late-stage respiratory pipeline. The Paris-based company has presented new Phase II data on amlitelimab, showing its ...

Sanofi would be the latest Big Pharma denizen to spin out its consumer or generic drug operations as separately traded entities. Johnson & Johnson (JNJ) spun out its consumer products division as ...

French pharma giant Sanofi reached a civil settlement ... induce healthcare providers to increase their prescriptions of Sanofi products. Charles Cain, FCPA unit chief at US SEC Enforcement ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Sanofi says the deal announced today will make it the world's number one consumer health company, with expected revenues of around €5.1 billion in 2015 ($5.61 billion) and a global market share ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...

The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ ... Qfitlia is a small interference RNA therapeutic that utilizes Alnylam Pharmaceutical Inc.'s (NASDAQ:ALNY) ESC-GalNAc ...